The Pharmaceutical Journal Only 24.5% of patients on metformin needed a second glucose-lowering medication, compared with 37.1% given a sulfonylurea , 39.6% treated with a thiazolidinedione and 36.2% with a DPP-4 inhibitor. For the latter three drugs, metformin was the most ...
Medical Research News and Interviews on MedicalResearch.com (blog) Dr. Hodson: Type 2 diabetes represents a huge socioeconomic challenge. As well as causing significant morbidity due to chronically elevated glucose levels, this disease is also a drain on healthcare budgets (~$20billion in the UK per year). While ...
The Pharmaceutical Journal Joanna is a freelance medical writer with a BSc (Hons) in Medical Science & Pharmacology and 15 years' experience working in the field of medical communications. Journalistic work includes clinical research summaries, interviews, feature articles and ...
JAMA: The Journal of the American Medical Association In Reply We agree with Drs Tasci and Safer that the risk of metformin and insulin compared with metformin plus sulfonylurea as a second-line diabetes treatment after failure of metformin monotherapy may differ in certain populations. They point to ... and more »
Farm Chemicals International (press release) ... well as higher disease pressure in spring across Northern Europe which boosted the sales of the fungicides portfolio. Rotam has also continued to increase its sulfonylurea market share on cereals which also benefited from the favorable climatic ...
Diabetes In Control While 24.5% patients on metformin required an add-on oral medication, 37.1% of patients on sulfonylurea , 39.6% of patients on thiazolidinedione, and 36.2% patients on DPP-4 inhibitor required an add-on oral medication. Moreover, 5.1% of patients on ...
American Pharmacists Association, pharmacist.com Approval of dulaglutide was based on data from five clinical trials, known as the AWARD studies, in which dulaglutide was studied as monotherapy (n = 807) and in combination with metformin (n = 972), metformin and sulfonylurea (n = 807), metformin and ...
Clinical Advisor In patients prescribed a sulfonylurea , a thiazolidinedione, or a DPP-4 inhibitor added a second drug to their diabetes treatment regimen during the st...
Diabetes News Journal Researchers used the information from medical and prescription insurance claims, and concluded that individuals treated with sulfonylurea (SFU), dipeptidyl peptidase-4 (DPP-4) inhibitor, and thiazolidinedione (TZD) were significantly more likely to ...
Daily Nebraskan The next step is placing a liquid solution containing sulfonylurea , a class of antidiabetic drugs, into the column to observe the drug-protein bonding over a certain period of time. The final step is to compare the results of both the healthy samples ...
